83 related articles for article (PubMed ID: 17408743)
1. Difference of T cell and B cell activation in two homologous proteins with similar antigenicity but great distinct immunogenicity.
Wu T; Wu XL; Ou SH; Lin CX; Cheng T; Li SW; Ng MH; Zhang J; Xia NS
Mol Immunol; 2007 May; 44(12):3261-6. PubMed ID: 17408743
[TBL] [Abstract][Full Text] [Related]
2. [Priming with an HEV Th epitope can improve the humoral immunogenicity of its native protein].
Lin CX; Wu T; Wu XL; Xie MH; Cheng T; Li SW; Zhang J; Xia NS
Sheng Wu Gong Cheng Xue Bao; 2007 Mar; 23(2):310-4. PubMed ID: 17460907
[TBL] [Abstract][Full Text] [Related]
3. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates.
Li SW; Zhang J; Li YM; Ou SH; Huang GY; He ZQ; Ge SX; Xian YL; Pang SQ; Ng MH; Xia NS
Vaccine; 2005 Apr; 23(22):2893-901. PubMed ID: 15780738
[TBL] [Abstract][Full Text] [Related]
4. [Particulate recombinant hepatitis E virus capsid protein and its antigenicity and immunogenicity].
He ZQ; Zhang J; Li SW; Lin J; Liu RS; Chen YX; Wang YB; Xia NS
Sheng Wu Gong Cheng Xue Bao; 2004 Mar; 20(2):262-8. PubMed ID: 15969119
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of candidate hepatitis E virus DNA vaccine expressing complete and truncated ORF2 in mice.
Deshmukh TM; Lole KS; Tripathy AS; Arankalle VA
Vaccine; 2007 May; 25(22):4350-60. PubMed ID: 17459540
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A.
Wang K; Zhou L; Zhang X; Song C; Chen T; Li J; Zheng M; Wang Y; Zheng Q; Zheng Z; Yu H; Wu T; Gu Y; Zhang J; Zhao Q; Li S; Xia N
Antiviral Res; 2019 Apr; 164():154-161. PubMed ID: 30802475
[TBL] [Abstract][Full Text] [Related]
7. Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine.
Fei-fei G; Jian W; Feng X; Li-ping S; Quan-yun S; Jin-ping Z; Pu-yan C; Pei-hong L
Vaccine; 2008 Oct; 26(44):5590-4. PubMed ID: 18761388
[TBL] [Abstract][Full Text] [Related]
8. Specific memory B cell response and participation of CD4
Kulkarni SP; Thanapati S; Arankalle VA; Tripathy AS
Vaccine; 2016 Nov; 34(48):5895-5902. PubMed ID: 27997340
[TBL] [Abstract][Full Text] [Related]
9. [Immunogenicity of recombinant HEV ORF2 protein expressed in pichia pastoris].
Tong Y; Zhan M; Lu J; Bai Y; Bi S
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Mar; 16(1):23-6. PubMed ID: 11986739
[TBL] [Abstract][Full Text] [Related]
10. Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice.
Renoux VM; Fleury MJ; Bousarghin L; Gaitan J; Sizaret PY; Touzé A; Coursaget P
Vaccine; 2008 Dec; 26(51):6602-7. PubMed ID: 18835319
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization.
Denis J; Majeau N; Acosta-Ramirez E; Savard C; Bedard MC; Simard S; Lecours K; Bolduc M; Pare C; Willems B; Shoukry N; Tessier P; Lacasse P; Lamarre A; Lapointe R; Lopez Macias C; Leclerc D
Virology; 2007 Jun; 363(1):59-68. PubMed ID: 17320136
[TBL] [Abstract][Full Text] [Related]
12. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
13. The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E.
Dong C; Dai X; Meng JH
Vaccine; 2007 Feb; 25(9):1662-8. PubMed ID: 17156900
[TBL] [Abstract][Full Text] [Related]
14. Characterization of antigenic epitopes of the ORF2 protein from hepatitis E virus genotype 4.
Zhang H; Dai X; Shan X; Meng J
Virus Res; 2009 Jun; 142(1-2):140-3. PubMed ID: 19428747
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of the highly pathogenic porcine reproductive and respiratory syndrome virus GP5 protein encoded by a synthetic ORF5 gene.
Li B; Xiao S; Wang Y; Xu S; Jiang Y; Chen H; Fang L
Vaccine; 2009 Mar; 27(13):1957-63. PubMed ID: 19368777
[TBL] [Abstract][Full Text] [Related]
16. [The immuno-protect study of a hepatitis E virus ORF2 peptide expressed in E. coli].
Ge S; Zhang J; Huang G; Pang S; Zhou K; Xia N
Wei Sheng Wu Xue Bao; 2003 Feb; 43(1):35-42. PubMed ID: 16276869
[TBL] [Abstract][Full Text] [Related]
17. Challenge studies in Rhesus monkeys immunized with candidate hepatitis E vaccines: DNA, DNA-prime-protein-boost and DNA-protein encapsulated in liposomes.
Arankalle VA; Lole KS; Deshmukh TM; Srivastava S; Shaligram US
Vaccine; 2009 Feb; 27(7):1032-9. PubMed ID: 19095027
[TBL] [Abstract][Full Text] [Related]
18. In vitro human CD4+ T cell response to the vaccinia protective antigens B5R and A33R.
Sirven P; Castelli FA; Probst A; Szely N; Maillere B
Mol Immunol; 2009 Apr; 46(7):1481-7. PubMed ID: 19193441
[TBL] [Abstract][Full Text] [Related]
19. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
